NAKANO et al. U.S. National Phase of PCT/JP2004/015315

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Original) A cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the cell is naturalized in a serum-free medium.
- 2. (Original) The cell according to claim 1, wherein all of alleles on a genome encoding an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain are knocked out, and wherein the cell is naturalized in a serum-free medium.
- 3. (Currently Amended) The cell according to claim 1-or-2, wherein an exon region containing an initiation codon of the genomic gene encoding an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is deleted, and wherein the cell is naturalized in a serum-free medium.

- 4. (Currently Amended) The cell according to any one of claims 1 to 3, wherein the enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is  $\alpha$ -1,6-fucosyltransferase.
- 5. (Original) The cell according to claim 4, wherein the  $\alpha$ -1,6-fucosyltransferase is a protein encoded by a DNA selected from the following (a) or (b):
- (a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:1;
- (b) a DNA which hybridizes with a DNA consisting of the nucleotide sequence represented by SEQ ID NO:1 under stringent conditions and encodes a protein having  $\alpha$ -1,6-fucosyltransferase activity.
- 6. (Original) The cell according to claim 4, wherein the  $\alpha$ -1,6-fucosyltransferase is a protein selected from the group consisting of the following (a), (b) and (c):
- (a) a protein comprising the amino acid sequence represented by SEQ ID NO:5;
- (b) a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:5 and having  $\alpha$ -1,6-fucosyltransferase activity;

## NAKANO et al. U.S. National Phase of PCT/JP2004/015315

- (c) a protein consisting of an amino acid sequence which has at least 80% amino acid sequence homology to the amino acid sequence represented by SEQ ID NO:5 and having  $\alpha$ -1,6-fucosyltransferase activity.
- 7. (Currently Amended) The cell according to any one of claims 1 to 6, which is resistant to a lectin which recognizes a sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain.
- 8. (Original) The cell according to claim 7, wherein said resistance is resistance in which the cell survives at a higher ratio than a cell in which the genomic gene has not been knocked out when the cells are cultured in a medium containing the lectin which recognizes a sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain.
- 9. (Currently Amended) The cell according to any one of claims 1 to 7, wherein the serum-free medium is a protein-free medium.
- 10. (Currently Amended) The cell according to any one of claims 1 to 9, which comprises a gene encoding a glycoprotein.

NAKANO et al.

## U.S. National Phase of PCT/JP2004/015315

- 11. (Original) The cell according to claim 10, wherein the glycoprotein is a glycoprotein having no sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain.
- 12. (Currently Amended) The cell according to claim 10 or 11, wherein the glycoprotein is an antibody.
- 13. (Original) The cell according to claim 12, wherein the antibody belongs to an IgG class.
- 14. (Currently Amended) A process for producing a glycoprotein composition, which comprises using the cell according to any one of claims 1-to 13.
- 15. (Currently Amended) A process for producing a glycoprotein composition, which comprises culturing the cell according to any one of claims 1 to 13-in a medium to form and accumulate the glycoprotein composition in the culture, and recovering and purifying the glycoprotein composition from the culture.
- 16. **(Original)** The process for producing a glycoprotein composition according to claim 14 or 15, wherein the process is carried out by batch culture, fedbatch culture or perfusion culture.

- 17. (Currently Amended) The process according to any one of claims 14 or 15 to 16, wherein at least one selected from a nutrient factor and a physiologically active substance is added to the medium during culturing.
- 18. **(Original)** The process according to claim 17, wherein the nutrient factor is at least one selected from a glucose, an amino acid and a vitamin.
- 19. **(Original)** The process according to claim 17, wherein the physiologically active substance is at least one selected from an insulin, an insulin-like growth factor, transferrin and albumin.
- 20. (Currently Amended) The process according to any one of claims 14 or 15to 16, wherein the glycoprotein composition is an antibody composition.
- 21. (Original) A method for naturalizing a cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is knocked out in a serum-free medium, which comprises inoculating the cell into a medium for naturalization to give a cell density of  $1\times10^5$  to  $1\times10^6$  cells/ml.

- 22. (Original) A method for obtaining a clone in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is knocked out, which comprises naturalizing the cell in a serum-free medium by the method according to claim 21, and then cloning the cell.
- 23. (Original) A cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the cell is naturalized in a serum-free medium, which is obtainable by the method according to claim 21.
- 24. (Original) A clone in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the clone is naturalized in a serum-free medium, which is obtainable by the method according to claim 22.
- 25. (Original) The method according to claim 21 or 22, wherein the serum-free medium is a protein-free medium,

## NAKANO et al. U.S. National Phase of PCT/JP2004/015315

- 26. (Original) The cell according to claim 23, wherein the serum-free medium is a protein-free medium.
- 27. **(Original)** The clone according to claim 24, wherein the serum-free medium is a protein-free medium.